ADAKVEO ® (crizanlizumab-tmca) is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients, aged 16 years and older, with sickle cell disease.
ADAKVEO is administered by IV infusion over a period of 30 minutes at Weeks 0 and 2, then every 4 weeks.
Before you attend your first appointment at Sage Infusion, please make sure to review the documents below. The Patient Consent Form and HIPAA Privacy Authorization Form need to be filled out and signed ahead of your appointment, whereas the Notice of Privacy Practices, Patient Rights and Responsibilities, and Appointment Lateness and Cancelation are for reference only. Please contact us if you have any questions!
Find a Sage Infusion Location Near You
We offer expert infusion therapy without the hassle or cost of the hospital. We employ highly trained medical staff that work with health insurance companies & physicians to provide our patients with convenient care.
SEARCH BY ZIP